EGFR and head and neck cancer: Currently, a global Phase 3 clinical trial using an antibody against epidermal growth factor receptor (EGFR) conjugated to IR700 molecule (Cetuximab-IR700) is being tested in patients with recurrent head and neck cancers [35].